NCT03511456 is a clinical trial of PELD operation in Neuralgia, Sciatic, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT03511456?

NCT03511456 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT03511456?

Interventions in NCT03511456: PELD operation.

What condition does NCT03511456 study?

NCT03511456 studies Neuralgia, Sciatic.

Is NCT03511456 still recruiting?

NCT03511456 is currently status unknown. Last updated 8 February 2021.

Last reviewed 2021-02-08 · How we verify

NCT03511456

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Effect and Safety Observation on PELD Technique for Extraforaminal Disc Herniation at L5/S1

Status unknown Last updated 8 February 2021

What this trial tests

trial testing PELD operation in Neuralgia, Sciatic in 30 participants. Status unknown.

Timeline

5 March 2016

Primary endpoint
1 July 2021

5 March 2022

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	5 March 2016
Primary completion	1 July 2021
Estimated completion	5 March 2022
Sites	1 location across China

Drugs / interventions tested

PELD operation

Conditions studied

Neuralgia, Sciatic — all drugs for Neuralgia, Sciatic →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 30 to 75, any sex, with Neuralgia, Sciatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

43% or so of far lateral lumbar disc herniation (FLLDH) occurred at L5/S1, however, the surgical treatment is still quite challenging. We conducted a modified PELD technique that enable us to remove the extraforaminal herniated disc at L5/S1, through the anatomical space surrounded by transverse process, facet joint and sacrum (TFS space). This study is to this technique's effect and safety in a one year follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03511456 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 8 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing